A new UCLA study found that while traditional pathological features used to classify aggressive prostate cancer —such as high-grade disease, cancer extending outside the prostate and cancer involving the seminal vesicles— after surgery can help identify patients who are more likely to have worse outcomes, they do not predict who will benefit more from adding hormone therapy to postoperative radiation. 

The University of Chicago Medicine Comprehensive Cancer Center (UCCCC) and Eli Lilly and Company (Lilly) have partnered to help patients gain greater access to potential cancer treatments by participating in clinical trials.

Researchers at the University of Colorado Anschutz Cancer Center have identified a previously unknown metabolic weakness in the stem cells that drive high-risk myelodysplastic syndromes (MDS), a discovery that could lead to more targeted treatments for this aggressive blood cancer.

About the Study: Which patient populations with non–small cell lung cancer (NSCLC) with a mutation in the epidermal growth factor receptor (EGFR) would benefit from a first-line treatment of an intensified combination therapy? In this randomized phase 3 study including 294 patients with advanced NSCLC and an EGFR mutation and concurrent TP53 mutations, first-line osimertinib plus chemotherapy significantly improved median progression-free survival compared with osimertinib alone (34.0 months vs 15.6 months; hazard ratio for disease progression or death, 0.44). This study provides evidence for incorporating TP53-based molecular risk stratification into first-line clinical decision-making because the efficacy of intensified combination therapy justifies the added treatment-related burden in this high-risk population.

A team led by researchers from the German Cancer Research Center (DKFZ), the HI-STEM* Stem Cell Institute, and Medical Clinic V at Heidelberg University Hospital (UKHD) has characterized T cells in the bone marrow in cases of multiple myeloma and acute myeloid leukemia: A specific group of tumor-reactive T cells can recognize and, in principle, fight cancer cells, but is often not sufficiently activated. Nevertheless, the number of these cells influences the prognosis. A specific gene signature identifies the tumor-reactive T cells and could predict the success of immunotherapies.

A new study finds the cost-effectivenss of perioperative pembrolizumab for advanced head and neck squamous cell carcinoma may depend on patients' combined positive scores.

New research from The University of Texas at Arlington helps explain a longstanding puzzle in melanoma treatment: why continuous targeted therapy performed better than planned on-and-off treatment schedules in clinical trials, despite promising laboratory studies of intermittent dosing.